**Appendix Table E50. Phenotypic test details in a single study assessing the predictive ability of VASP in patients with ischemic heart, cerebrovascular and peripheral vascular disease**

| **Author, year [ref]****UID****Country****Study Name** | **Test/Device name** **Device category Device name & manufacturer\*** | **Agonist used** | **Sample Collection and Procurement****Anticoagulant used****Interval between clopidogrel doses and blood sampling (in days)** **Interval between sampling and testing (in days):** | **Grouping of Phenotypes [Definition]**  | **Rational for the grouping of phenotypes reported (Yes/No)** **[short description]** | **Frequency of phenotypes**  |
| --- | --- | --- | --- | --- | --- | --- |
| Reny, 2012{Reny, 2012 18240 /id}22615340France and SwitzerlandADRIE | VASPFACS Calibur flow cytometerBecton Dickinson, san Jose, CA, USAVASP/P2Y12 kit (BioCytex, Marseille,France)  | ADP+PGE1 (prostaglandin E1)  | Blood samples collected after antiplatelet therapy intake0.105 mol/L sodium citrate (1vol/9 vol)3 hrsNR | PRI ≥50% PRI <50% | Based on literature | ≥50%: 226<50%: 221 |